Healthcare review: Tranzyme, AcelRx, Gilead Sciences, AspenBio Pharma, Threshold Pharmaceuticals Are Notable Movers Print E-mail
By Staff and Wire Reports   
Thursday, 15 November 2012 15:18
The S&P 500 was on track to fall for a third day on Thursday as Wal-Mart Stores Inc reported disappointing results and investors feared the "fiscal cliff" will harm the economy.

Stocks have struggled recently to hold onto even slight gains, dropping more than 1 percent on Wednesday after starting the session higher. Investors worry the economy could slip into recession if no deal is reached in Washington to avoid the fiscal cliff - budget cuts and tax hikes that begin to take effect in the new year. The S&P 500 is off about 2 percent for the week so far.

Following are the notable movers at mid day on Thursday:

Tranzyme Inc(NASDAQ:TZYM) plunged 76% t after reporting negative preliminary results from the first of two trials assessing its TZP-102 treatment for diabetic patients with a common stomach complication. Neither the 10mg dose group nor the 20mg dose group of TZP-102 patients reached statistical significance vs. a placebo.

AcelRx Pharmaceuticals Inc(NASDAQ:ACRX) climbed 6.60% after saying that its under-the-tongue NanoTab system for relieving pain after surgery came out on top in a direct head-to-head with morphine in a Phase III trial. Patients loved it and so did nurses. NanoTab system is being tested in two other late-stage studies.

Gilead Sciences, Inc.(NASDAQ:GILD) says Phase 3 clinical trial results from its study comparing single tablet regimens of Complera versus Atripla in adults with HIV infection demonstrated that Complera - which is marketed as Eviplera in the E.U. - showed a statistically significant difference in efficacy compared to Atripla among patients with low baseline viral load, and was non-inferior to Atripla among patients with high baseline viral load. Separately, the company also reports that two-year results from two Phase 3 tests of it's newest single tablet HIV regimen, Stribild, also showed it was non-inferior after two years of treatment as compared to two other standard HIV regimens. Shares of the company are up 0.50% to $72.66.

AspenBio Pharma, Inc.(NASDAQ:APPY) slid 14% after pricing its previously announced secondary offering of 1.5M shares at $2.10 each, a 15% discount to Wednesday's close. The diagnostic-product developer has a 7.7M share float outstanding at the beginning of November.

Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) added 5% an updated results from a Phase II trial of Threshold's (THLD) TH-302 treatment suggest that the drug can be used in patients with soft-tissue sarcoma, first in combination with chemotherapy doxorubicin, and then on its own as a maintenance treatment. The results support Phase III trials of the regimen.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter